Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
Spain
Clinica Universidad de Navarra, Pamplona, Navarre Complejo Hospittalario de Navarra, Pamplona, Navarre